NASDAQ : LEGN
Legend Biotech Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 22.3 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.32B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.19B |
| Enterprise Value | 3.50B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 193.77M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +4.70% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 52.90% |
| Float | 90.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 49.16 |
| PS Ratio | 3.30 |
| Forward PS | 2.60 |
| PB Ratio | 3.41 |
| P/TBV Ratio | 3.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.04 |
| Quick Ratio | 2.88 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.24 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -8.08% |
| Return on Assets (ROA) | -1.92% |
| Return on Invested Capital (ROIC) | -9.91% |
| Return on Capital Employed (ROCE) | -3.92% |
| Weighted Average Cost of Capital (WACC) | 7.36% |
| Revenue Per Employee | $428,803 |
| Profits Per Employee | -$30,860 |
| Employee Count | 2,965 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 14.32 |
Taxes
| Measure | Value |
|---|
| Income Tax | 35.30M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -32.68% |
| 50-Day Moving Average | 19.55 |
| 200-Day Moving Average | 22.13 |
| Relative Strength Index (RSI) | 61.65 |
| Average Volume (20 Days) | 1,978,397 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13.90M |
| Short Previous Month | 16.39M |
| Short % of Shares Out | 16.91% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.10 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.27B |
| Gross Profit | 719.30M |
| Operating Income | -52.80M |
| Pretax Income | -56.20M |
| Net Income | -91.50M |
| EBITDA | -41.60M |
| EBIT | -52.80M |
| Loss Per Share | -$0.50 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 964.60M |
| Total Debt | 278.20M |
| Net Cash | 686.40M |
| Net Cash Per Share | $3.54 |
| Equity (Book Value) | 1.23B |
| Book Value Per Share | 6.35 |
| Working Capital | 823.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -89.40M |
| Capital Expenditures | -32.40M |
| Depreciation & Amortization | 11.20M |
| Net Borrowing | -47.80M |
| Free Cash Flow | -121.80M |
| FCF Per Share | -$0.63 |
Margins
| Measure | Value |
|---|
| Gross Margin | 56.58% |
| Operating Margin | -4.15% |
| Pretax Margin | -4.42% |
| Profit Margin | -7.20% |
| EBITDA Margin | -3.27% |
| EBIT Margin | -4.15% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | -2.32% |
| FCF Yield | -2.91% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $45.62 |
| Price Target Difference | 110.91% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 24.69% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.57 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |